Aerie plans to use the money for supporting and promoting its glaucoma drug candidate through clinical trials. The company has raised $63.5 million from investors since it was founded in 2005.
More Articles on Ophthalmology:
5 Ways Healthcare Reform Will Impact Ophthalmologists
Ophthalmic Laser Company Lumenis Receives FDA 510(k) Approval
Ophthalmologist Dr. Benjamin Hale Joins Geisinger Health System in Pennsylvania
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.